Prokidney Corp. financial data

Symbol
PROK on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
2000 Frontis Plaza Blvd., Suite 250, Winston Salem, NC
State of incorporation
Cayman Islands
Fiscal year end
December 31
Former names
Social Capital Suvretta Holdings Corp. III (to 7/11/2022)
Latest financial report
10-Q - Q3 2024 - Nov 12, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.77K % -35.6%
Debt-to-equity -2.7 % -76.6%
Return On Equity 4.39 %
Return On Assets -10.2 %

Shares

Label TTM Value / Value Unit Change %
Entity Public Float 689M USD -99.7%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 110M USD +5.09%
General and Administrative Expense 45.9M USD -12.5%
Operating Income (Loss) -156M USD +0.78%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -136M USD +0.2%
Income Tax Expense (Benefit) 491K USD -74.7%
Net Income (Loss) Attributable to Parent -45.6M USD -63.1%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 108M USD -43.5%
Other Assets, Current 1.03M USD +34267%
Assets, Current 430M USD +5.86%
Property, Plant and Equipment, Net 38.5M USD -9.61%
Operating Lease, Right-of-Use Asset 5.94M USD +132%
Assets 475M USD +5.09%
Accounts Payable, Current 2.85M USD -36.3%
Accrued Liabilities, Current 21.3M USD +37.5%
Liabilities, Current 25.2M USD +20%
Accrued Income Taxes, Noncurrent 772K USD +47.9%
Operating Lease, Liability, Noncurrent 5.29M USD +166%
Liabilities 31.3M USD +32.6%
Accumulated Other Comprehensive Income (Loss), Net of Tax 321K USD
Retained Earnings (Accumulated Deficit) -1.18B USD -4.02%
Stockholders' Equity Attributable to Parent -980M USD +10.3%
Liabilities and Equity 475M USD +5.09%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -34.6M USD -33.3%
Net Cash Provided by (Used in) Financing Activities 25.5M USD
Net Cash Provided by (Used in) Investing Activities 58.4M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 23.7M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 108M USD -43.5%
Deferred Tax Assets, Valuation Allowance 12.9M USD +287%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Cash and Cash Equivalents, Period Increase (Decrease) -389K USD
Deferred Tax Assets, Gross 14.4M USD +182%
Operating Lease, Liability 6.32M USD +142%
Depreciation 3.87M USD +42.8%
Payments to Acquire Property, Plant, and Equipment 960K USD -2.64%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -45.2M USD -61%
Lessee, Operating Lease, Liability, to be Paid 8.38M USD +167%
Operating Lease, Liability, Current 1.03M USD +65.1%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.84M USD +117%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.68M USD +100%
Operating Lease, Weighted Average Discount Rate, Percent 0.11 pure +10.5%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 2.06M USD +298%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.73M USD +123%
Deferred Tax Assets, Operating Loss Carryforwards 294K USD
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 1.36M USD +211%
Operating Lease, Payments 279K USD +37.4%
Additional Paid in Capital 200M USD +382%
Preferred Stock, Shares Outstanding 0 shares
Amortization of Intangible Assets 213K USD -0.93%
Depreciation, Depletion and Amortization 1.1M USD +32.5%
Deferred Tax Assets, Net of Valuation Allowance 1.49M USD -15.1%
Share-based Payment Arrangement, Expense 16.1M USD -65.2%
Interest Expense 10K USD 0%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%